Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 580Neoplasms 488Prostatic Neoplasms 311Lung Neoplasms 236Colorectal Neoplasms 199Motor Activity 131Carcinoma, Non-Small-Cell Lung 117Uterine Cervical Neoplasms 112Brain Neoplasms 110Pancreatic Neoplasms 109Head and Neck Neoplasms 106Stomach Neoplasms 99Carcinoma, Hepatocellular 98Rectal Neoplasms 97Ovarian Neoplasms 86Colonic Neoplasms 86Neoplasm Metastasis 67Multiple Myeloma 65Esophageal Neoplasms 65Hematologic Neoplasms 62Urinary Bladder Neoplasms 60Glioblastoma 59Melanoma 58Sarcoma 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Endometrial Neoplasms 56Glioma 53Lymphoma 50Leukemia, Myeloid, Acute 48Gastrointestinal Neoplasms 48

Interventions

Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Recruiting × Early Hormone Receptor-positive Breast Cancer × Clear all
NCT04278469 2020-02-20

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Gencurix, Inc.

Phase NA Recruiting
194 enrolled
Breast

Early Hormone Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡